X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-20

Reporting Person: Ross Michael Jay (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-20	Common Stock	C	19128	—	Acquired	19128	Indirect
2017-11-20	Common Stock	C	404	—	Acquired	19532	Indirect
2017-11-20	Common Stock	C	247010	—	Acquired	266542	Indirect
2017-11-20	Common Stock	C	5219	—	Acquired	271761	Indirect
2017-11-20	Common Stock	C	322102	—	Acquired	593863	Indirect
2017-11-20	Common Stock	C	6806	—	Acquired	600669	Indirect
2017-11-20	Common Stock	C	111955	—	Acquired	712624	Indirect
2017-11-20	Common Stock	C	2365	—	Acquired	714989	Indirect
2017-11-20	Common Stock	C	202915	—	Acquired	917904	Indirect
2017-11-20	Common Stock	C	4288	—	Acquired	922192	Indirect
2017-11-20	Common Stock	C	431980	—	Acquired	1354172	Indirect
2017-11-20	Common Stock	C	14789	—	Acquired	1368961	Indirect
2017-11-20	Common Stock	P	483448	$10.00	Acquired	1852409	Indirect
2017-11-20	Common Stock	P	16552	$10.00	Acquired	1868961	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-20	Series A-1 Convertible Preferred Stock	$	C	65287	Disposed		Common Stock (19128)	Indirect
2017-11-20	Series A-1 Convertible Preferred Stock	$	C	1380	Disposed		Common Stock (404)	Indirect
2017-11-20	Series A-2 Convertible Preferred Stock	$	C	690259	Disposed		Common Stock (247010)	Indirect
2017-11-20	Series A-2 Convertible Preferred Stock	$	C	14587	Disposed		Common Stock (5219)	Indirect
2017-11-20	Series B Convertible Preferred Stock	$	C	721402	Disposed		Common Stock (322102)	Indirect
2017-11-20	Series B Convertible Preferred Stock	$	C	15246	Disposed		Common Stock (6806)	Indirect
2017-11-20	Series C Convertible Preferred Stock	$	C	224665	Disposed		Common Stock (111955)	Indirect
2017-11-20	Series C Convertible Preferred Stock	$	C	4747	Disposed		Common Stock (2365)	Indirect
2017-11-20	Series D Convertible Preferred Stock	$	C	692552	Disposed		Common Stock (202915)	Indirect
2017-11-20	Series D Convertible Preferred Stock	$	C	14635	Disposed		Common Stock (4288)	Indirect
2017-11-20	Series D Convertible Preferred Stock	$	C	1474348	Disposed		Common Stock (431980)	Indirect
2017-11-20	Series D Convertible Preferred Stock	$	C	50477	Disposed		Common Stock (14789)	Indirect

Footnotes

F1: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F2: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F3: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F4: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F5: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F6: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F7: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F8: These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F9: These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.